BridgeMD
New treatment option for Hypermobility, Joint
Official title Exercise in Patients With Hypermobile Joints and Knee Pain
ClinicalTrials.gov ID: NCT06277401
What this study is testing
- What it's testing
- Pain associated with knee joint hypermobility is common in the adult population, but evidence on treatment is sparse. This study investigates if high-load resistance training is superior to usual care in improving activity-related pain in young patients (18-45 years) with hypermobile joints and knee pain.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 45
You may be able to join if
- Persistent knee pain for ≥ 3 months (self-reported)
- Knee pain ≥ 30mm during the last week using a 0-100 mm visual analogue scale (VAS; 0=no pain and 100=worst imaginable pain) (self-reported)
- Generalised joint hypermobility assessed with the Five-Part Hypermobility Questionnaire (positive ≥ 2/5) (self-reported)
- Local knee joint hypermobility using the passive hyperextension of the knee in standing (positive \> 10 degrees of hyperextension) and confirmed in...
You likely can't join if
- Diagnosed with patellar tendinopathy
- Pregnancy or childbirth within the past year (due to increased levels of relaxin that could affect joint stability)
- Knee surgery within the past year
- Participation in regular structured resistance training within the past six months
- Inability to speak and understand Danish.
- All types of Ehlers-Danlos syndrome
See the full eligibility criteria
- Persistent knee pain for ≥ 3 months (self-reported)
- Knee pain ≥ 30mm during the last week using a 0-100 mm visual analogue scale (VAS; 0=no pain and 100=worst imaginable pain) (self-reported)
- Generalised joint hypermobility assessed with the Five-Part Hypermobility Questionnaire (positive ≥ 2/5) (self-reported)
- Local knee joint hypermobility using the passive hyperextension of the knee in standing (positive \> 10 degrees of hyperextension) and confirmed in supine lying (heel resting on 20 cm high block on the bench surface)...
- Diagnosed with patellar tendinopathy
- Pregnancy or childbirth within the past year (due to increased levels of relaxin that could affect joint stability)
- Knee surgery within the past year
- Participation in regular structured resistance training within the past six months
- Inability to speak and understand Danish.
- All types of Ehlers-Danlos syndrome
- Other heritable connective tissue disorders such as Marfan syndrome, osteogenesis imperfecta, Loeys-Dietz syndrome, Stickler syndrome, skeletal dysplasias
- Autoimmune rheumatic connective tissue disorders such as lupus, rheumatoid arthritis; Chromosomal conditions such as Fragile X syndrome, Kabuki syndrome, Down syndrome
- Neuromuscular disorders that can cause joints to become unstable, such as multiple sclerosis
The study team makes the final eligibility decision.
Where it's taking place
- Odense, Fyn, Denmark
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 45 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Odense, Fyn, Denmark. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.